Monday, November 23, 2009, 11:39am EST - Canadian Markets close in 4 hours and 21 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Rosetta Genomics, Ltd. (ROSG)

 At 10:51 EST: 2.14 USD  Down 0.07 (3.01%)  
MORE ON ROSG
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Rosetta Genomics Ltd. (NGM:ROSG) Delayed quote dataEdit
Last Trade: 2.14 USD
Trade Time: 10:51AM EST
Change: Down 0.07 (3.01%)
Prev Close: 2.21
Open: 2.14
Bid: 2.14 x 100
Ask: 2.20 x 700
1y Target Est: N/A
Day's Range: 2.14 - 2.14
52wk Range: 1.08 - 3.80
Volume: 200
Avg Vol (3m): 17,348.5
Market Cap: 29.06M
P/E (ttm): N/A
EPS (ttm): -0.92
Div & Yield: N/A (N/A%)
Rosetta Genomics, Ltd. (ROSG)
1d  5d  3m  6m  1y  2y  5y 
 Add ROSG to Portfolio   Download Data

HEADLINES
• Rosetta Genomics Strengthens MicroRNA Intellectual Property Position with Receipt of Additional Patent
Business Wire (Thu, Nov 5)
• Rosetta Genomics Names Kenneth A. Berlin President and Chief Executive Officer
Business Wire (Tue, Nov 3)
• Rosetta Genomics to Present at Scientific Conference; Provides Update on Colon Cancer Diagnostic Program
Business Wire (Fri, Oct 30)
• Rosetta Genomics Names Genetic Technologies Limited Exclusive Distributor for Rosettas microRNA-based Assays in Australia, New Zealand and Singapore
Business Wire (Thu, Oct 22)
• Prometheus Launches ProOnc Dx Cancer Diagnostics Three New Tests Based on Breakthrough MicroRNA Technology
PRNewswire (Thu, Oct 15)
• Rosetta Genomics to Present at the 2009 Maxim Group Growth Conference
Business Wire (Tue, Sep 29)
• Rosetta Genomics downgraded by Cantor Fitzgerald
Briefing.com (Wed, Sep 9)
• ROSETTA GENOMICS LTD Earnings Call scheduled for 4:30 pm ET today
CCBN (Tue, Sep 8)
• Rosetta Genomics Reports Second Quarter Financial Results, Provides Business Update
Business Wire (Tue, Sep 8)
• AXA Diagnostics Named Exclusive Distributor for Rosetta Genomics microRNA-based Assays in Italy
Business Wire (Tue, Sep 8)
More Headlines for ROSG...
ANALYST
EPS Est (next year) () : N/A
EPS Est (in 2 years) () : N/A
Avg Rec (current)*: N/A
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Rosetta Genomics Ltd. develops microRNA-based diagnostic and therapeutic products in Israel. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA and are used in regulating protein production.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices